Clinical AI leader Aidoc has secured $150 million in Series E funding, bringing its total capital raised to over half a billion dollars. The round was led by Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Vision Fund 2, and NVIDIA’s venture arm, NVentures. The new capital comes less than a year after the firm’s previous growth round, signaling continued investor interest in enterprise-scale healthcare AI.
The funding arrives as health systems pivot away from fragmented, standalone AI tools toward unified architectures. Aidoc’s platform, aiOS, leverages its proprietary foundation model, CARE, which recently received FDA clearance for a comprehensive foundation model-based triage system in clinical imaging. Currently, Aidoc is deployed across nearly 2,000 hospitals, analyzing more than 60 million patient cases annually.
According to co-founder and CEO Elad Walach, the capital will be used to advance end-to-end AI across CT and X-ray modalities, with a goal of moving from “pixel to draft report” within the next two years. By 2030, Walach said every complex diagnostic decision should be supported by AI to enable earlier detection and reduce preventable error, as diagnostic errors and delays contribute to at least 400,000 deaths each year in the U.S.
Christian Resch, Partner at Goldman Sachs Alternatives, noted that “Aidoc pairs advanced technology with regulatory rigor in a way that few companies have achieved.” The investment will specifically drive the development of automated imaging draft reports, a move designed to streamline workflows for radiologists facing rising imaging volumes and workforce shortages.
